GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ind-Swift Laboratories Ltd (NSE:INDSWFTLAB) » Definitions » ROIC %

Ind-Swift Laboratories (NSE:INDSWFTLAB) ROIC % : 7.79% (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Ind-Swift Laboratories ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Ind-Swift Laboratories's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was 7.79%.

As of today (2024-04-29), Ind-Swift Laboratories's WACC % is 4.69%. Ind-Swift Laboratories's ROIC % is 5.02% (calculated using TTM income statement data). Ind-Swift Laboratories generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Ind-Swift Laboratories ROIC % Historical Data

The historical data trend for Ind-Swift Laboratories's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ind-Swift Laboratories ROIC % Chart

Ind-Swift Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.37 4.53 -1.16 -0.98 6.35

Ind-Swift Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.02 -25.17 6.46 10.91 7.79

Competitive Comparison of Ind-Swift Laboratories's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ind-Swift Laboratories's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's ROIC % distribution charts can be found below:

* The bar in red indicates where Ind-Swift Laboratories's ROIC % falls into.



Ind-Swift Laboratories ROIC % Calculation

Ind-Swift Laboratories's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Mar. 2023 is calculated as:

ROIC % (A: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2022 ) + Invested Capital (A: Mar. 2023 ))/ count )
=1815.207 * ( 1 - 44.72% )/( (15786.079 + 15815.907)/ 2 )
=1003.4464296/15800.993
=6.35 %

where

Invested Capital(A: Mar. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=18007.947 - 1888.192 - ( 333.676 - max(0, 3344.653 - 10753.324+333.676))
=15786.079

Invested Capital(A: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=18240.64 - 2193.192 - ( 231.541 - max(0, 3710.889 - 11645.17+231.541))
=15815.907

Ind-Swift Laboratories's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=1525.368 * ( 1 - 19.28% )/( (15806.251 + 0)/ 1 )
=1231.2770496/15806.251
=7.79 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=17992.768 - 1841.791 - ( 344.726 - max(0, 3216.84 - 11652.638+344.726))
=15806.251

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ind-Swift Laboratories  (NSE:INDSWFTLAB) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Ind-Swift Laboratories's WACC % is 4.69%. Ind-Swift Laboratories's ROIC % is 5.02% (calculated using TTM income statement data). Ind-Swift Laboratories generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases. Ind-Swift Laboratories earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Ind-Swift Laboratories ROIC % Related Terms

Thank you for viewing the detailed overview of Ind-Swift Laboratories's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ind-Swift Laboratories (NSE:INDSWFTLAB) Business Description

Traded in Other Exchanges
Address
SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh, PB, IND, 160 101
Ind-Swift Laboratories Ltd is engaged in the business of active pharmaceutical ingredients (API). The company caters to diverse therapeutic segments namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Parkinson's Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitor. Geographically, it derives a majority of revenue from Outside India.

Ind-Swift Laboratories (NSE:INDSWFTLAB) Headlines

No Headlines